FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Willem Nooijen

Research Profile

Procedures

Living Beings

Chemicals & Drugs

Disorders

Anatomy

Feces

Concepts & Ideas

Tissue Distribution

Co-author Network

Publications

TOP 3
Adriaan Bins; Henk Mallo; Johan Sein; Colette van den Bogaard; Willem Nooijen; Florry A Vyth-Dreese; Bastiaan Nuijen; Gijsbert C De Gast; John B A G Haanen
Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients.
Rosalie M Luiten; Esther W M Kueter; Wolter J Mooi; Maarten P W Gallee; Elaine M Rankin; Winald Gerritsen; Shirley M Clift; Willem Nooijen; Pauline Weder; Willeke F van de Kasteele; Johan Sein; Paul van den Berk; Omgo E Nieweg; Anton M Berns; Hergen Spits; Gijsbert C De Gast
Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
Natascha C V Verra; Daphne de Jong; Axel Bex; Diane Batchelor; Trees A M Dellemijn; Johan Sein; Willem Nooijen; Wim Meinhardt; Simon Horenblas; Gijsbert C De Gast; Florry A Vyth-Dreese
Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Willem Nooijen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Adriaan Bins; Henk Mallo; Johan Sein; Colette van den Bogaard; Willem Nooijen; Florry A Vyth-Dreese; Bastiaan Nuijen; Gijsbert C De Gast; John B A G Haanen
Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(2):234-9.
2005: Rosalie M Luiten; Esther W M Kueter; Wolter J Mooi; Maarten P W Gallee; Elaine M Rankin; Winald Gerritsen; Shirley M Clift; Willem Nooijen; Pauline Weder; Willeke F van de Kasteele; Johan Sein; Paul van den Berk; Omgo E Nieweg; Anton M Berns; Hergen Spits; Gijsbert C De Gast
Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(35):8978-91.
2005: Natascha C V Verra; Daphne de Jong; Axel Bex; Diane Batchelor; Trees A M Dellemijn; Johan Sein; Willem Nooijen; Wim Meinhardt; Simon Horenblas; Gijsbert C De Gast; Florry A Vyth-Dreese
Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy.
European urology 2005;48(3):527-33.
2003: Natascha C V Verra; R Jansen; Gerard Groenewegen; Henk Mallo; Marie José Kersten; Axel Bex; Florry A Vyth-Dreese; Johan Sein; Willeke F van de Kasteele; Willem Nooijen; M de Waal; Simon Horenblas; Gijsbert C De Gast
Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
British journal of cancer 2003;88(9):1346-51.
2003: Gijsbert C De Gast; Diane Batchelor; Marie José Kersten; Florry A Vyth-Dreese; Johan Sein; Willeke F van de Kasteele; Willem Nooijen; Omgo E Nieweg; M A de Waal; Willem Boogerd
Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.
British journal of cancer 2003;88(2):175-80.
2002: Gijsbert C De Gast; Florry A Vyth-Dreese; Willem Nooijen; C J C van den Bogaard; Johan Sein; M M J Holtkamp; G A M Linthorst; Joke W Baars; Jan H Schornagel; Sjoerd Rodenhuis
Reinfusion of autologous lymphocytes with granulocyte-macrophage colony-stimulating factor induces rapid recovery of CD4+ and CD8+ T cells after high-dose chemotherapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):58-64.
2000: Heleen A Bardelmeijer; Jos H Beijnen; Kenneth Brouwer; Hilde Rosing; Willem Nooijen; J H M Schellens; Olaf van Tellingen
Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(11):4416-21.
2000: Gijsbert C De Gast; H J Klümpen; Florry A Vyth-Dreese; Marie José Kersten; Natascha C V Verra; Johan Sein; Diane Batchelor; Willem Nooijen; Jan H Schornagel
Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1267-72.
1999: Olaf van Tellingen; Jos H Beijnen; Jaap Verweij; E J Scherrenburg; Willem Nooijen; Alex Sparreboom
Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10):2918-24.
1999: Olaf van Tellingen; manon huizing; VR Panday; J H M Schellens; Willem Nooijen; Jos H Beijnen
Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
British journal of cancer 1999;81(2):330-5.
1999: Anneke M Westermann; M M J Holtkamp; G A Linthorst; L van Leeuwen; E J Willemse; W C van Dijk; Willem Nooijen; Joke W Baars; Jan H Schornagel; Sjoerd Rodenhuis
At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(5):511-7.
1998: Olaf van Tellingen; M Kemper; F Tijssen; J van Asperen; Willem Nooijen; Jos H Beijnen
High-performance liquid chromatographic bio-analysis of PSC 833 in human and murine plasma.
Journal of chromatography. B, Biomedical sciences and applications 1998;719(1-2):251-7.
1998: Sjoerd Rodenhuis; Dick J Richel; ELSKEN VAN DER WALL; Jan H Schornagel; Joke W Baars; C C Koning; Johannes L Peterse; Jacques H Borger; Willem Nooijen; Roel Bakx; Otilia Dalesio; E J Th Rutgers
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
Lancet 1998;352(9127):515-21.
1998: Olaf van Tellingen; Willem Nooijen; L J Schaaf; Martin van der Valk; J van Asperen; RE Henrar; Jos H Beijnen
Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans.
Cancer research 1998;58(11):2410-6.
1998: Olaf van Tellingen; Cornelis J A Punt; Ahmad Awada; D J Wagener; Martine J Piccart; Y Groot; L J Schaaf; RE Henrar; Willem Nooijen; Jos H Beijnen
A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study.
Cancer chemotherapy and pharmacology 1998;41(5):377-84.
1998: Alex Sparreboom; Olaf van Tellingen; Willem Nooijen; J H Beijnen
Preclinical pharmacokinetics of paclitaxel and docetaxel.
Anti-cancer drugs 1998;9(1):1-17.
1997: Alex Sparreboom; J van Asperen; U Mayer; Alfred H Schinkel; J W Smit; D K Meijer; Piet Borst; Willem Nooijen; Jos H Beijnen; Olaf van Tellingen
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(5):2031-5.
1997: J van Asperen; Olaf van Tellingen; Alex Sparreboom; Alfred H Schinkel; Piet Borst; Willem Nooijen; Jos H Beijnen
Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
British journal of cancer 1997;76(9):1181-3.
1997: Olaf van Tellingen; Willem Boogerd; Willem Nooijen; Jos H Beijnen
The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue.
Cancer chemotherapy and pharmacology 1997;40(4):330-4.
1996: J van Asperen; Alfred H Schinkel; Jos H Beijnen; Willem Nooijen; Piet Borst; Olaf van Tellingen
Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.
Journal of the National Cancer Institute 1996;88(14):994-9.
1996: Alex Sparreboom; Olaf van Tellingen; manon huizing; Willem Nooijen; Jos H Beijnen
Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1996;681(2):355-62.
1996: Alex Sparreboom; Olaf van Tellingen; E J Scherrenburg; J J Boesen; manon huizing; Willem Nooijen; C Versluis; J H Beijnen
Isolation, purification and biological activity of major docetaxel metabolites from human feces.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(6):655-8.
1996: Sjoerd Rodenhuis; Anneke M Westermann; M J Holtkamp; Willem Nooijen; Joke W Baars; ELSKEN VAN DER WALL; Ineke Slaper-Cortenbach; Jan H Schornagel
Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(5):1473-83.
1996: Alex Sparreboom; Olaf van Tellingen; Willem Nooijen; Jos H Beijnen
Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Cancer research 1996;56(9):2112-5.
1996: Alex Sparreboom; Olaf van Tellingen; Willem Nooijen; Jos H Beijnen
Tissue distribution, metabolism and excretion of paclitaxel in mice.
Anti-cancer drugs 1996;7(1):78-86.
1996: Olaf van Tellingen; M T Kuck; L T Vlasveld; Sjoerd Rodenhuis; Willem Nooijen; Jos H Beijnen
Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion.
Cancer chemotherapy and pharmacology 1996;38(4):387-90.
1995: ELSKEN VAN DER WALL; Willem Nooijen; Joke W Baars; M J Holtkamp; J H Schorangel; Dick J Richel; E J Th Rutgers; Ineke Slaper-Cortenbach; C Ellen van der Schoot; Sjoerd Rodenhuis
High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach.
British journal of cancer 1995;71(4):857-62.
1995: Alex Sparreboom; Olaf van Tellingen; Willem Nooijen; Jos H Beijnen
Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;664(2):383-91.
1995: Alex Sparreboom; manon huizing; J J Boesen; Willem Nooijen; Olaf van Tellingen; Jos H Beijnen
Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces.
Cancer chemotherapy and pharmacology 1995;36(4):299-304.
1994: ELSKEN VAN DER WALL; Dick J Richel; M J Holtkamp; Ineke Slaper-Cortenbach; C Ellen van der Schoot; Otilia Dalesio; Willem Nooijen; Jan H Schornagel; Sjoerd Rodenhuis
Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(9):795-802.
1994: Olaf van Tellingen; E M Pels; RE Henrar; L J Schaaf; G E Padbury; Jos H Beijnen; Willem Nooijen
Fully automated high-performance liquid chromatographic method for the determination of carzelesin (U-80,244) and metabolites (U-76,073 and U-76,074) in human plasma.
Journal of chromatography 1994;652(1):51-8.
1994: Olaf van Tellingen; A L Sonneveldt; Jos H Beijnen; Willem Nooijen; J Jantina Kettenes-van den Bosch; C Versluis; Auke Bult
Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinleucinol in mice as determined by high-performance liquid chromatography.
Cancer chemotherapy and pharmacology 1994;33(5):425-34.
1994: J H Sips; Olaf van Tellingen; Willem Nooijen; Sjoerd Rodenhuis; W J Ten Bokkel Huinink; Jos H Beijnen
The pharmacokinetics of reduced folates after intraperitoneal and intravenous administration of racemic [6S,R]-folinic acid.
Cancer chemotherapy and pharmacology 1994;35(2):144-8.
1993: Olaf van Tellingen; Jos H Beijnen; Willem Nooijen; Auke Bult
Plasma pharmacokinetics of vinblastine and the investigational Vinca alkaloid N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate in mice as determined by high-performance liquid chromatography.
Cancer research 1993;53(9):2061-5.
1993: Olaf van Tellingen; A V Kuijpers; Jos H Beijnen; Willem Nooijen; Auke Bult
Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography.
Investigational new drugs 1993;11(2-3):141-50.
1993: Olaf van Tellingen; Jos H Beijnen; Willem Nooijen; Auke Bult
Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography.
Cancer chemotherapy and pharmacology 1993;32(4):286-92.
1992: Peter Bruning; J M Bonfrèr; Paulus A H van Noord; Augustinus A M Hart; M de Jong-Bakker; Willem Nooijen
Insulin resistance and breast-cancer risk.
International journal of cancer. Journal international du cancer 1992;52(4):511-6.
1992: Olaf van Tellingen; J H Sips; Jos H Beijnen; Auke Bult; Willem Nooijen
Pharmacology, bio-analysis and pharmacokinetics of the vinca alkaloids and semi-synthetic derivatives (review).
Anticancer research 1992;12(5):1699-715.
1992: Peter Bruning; J M Bonfrèr; Augustinus A M Hart; Paulus A H van Noord; H van der Hoeven; HJ Collette; J J Battermann; M de Jong-Bakker; Willem Nooijen; F de Waard
Body measurements, estrogen availability and the risk of human breast cancer: a case-control study.
International journal of cancer. Journal international du cancer 1992;51(1):14-9.
1992: Johannes M G Bonfrer; H M de Graaf; Willem Nooijen
Breast cancer mucin: an automated assay to detect mucus glycoproteins.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1992;13(3):162-7.
1992: P F Peerboom; E A Hassink; R Melkert; L G H Dewit; Willem Nooijen; Peter Bruning
Thyroid function 10-18 years after mantle field irradiation for Hodgkin's disease.
European journal of cancer (Oxford, England : 1990) 1992;28A(10):1716-8.
1990: Peter Bruning; J M Bonfrèr; J Wildiers; J Jassem; L V Beex; Jan H Schornagel; Willem Nooijen
Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-arm randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861).
The Journal of steroid biochemistry and molecular biology 1990;37(6):1013-9.
1990: L G H Dewit; J K Anninga; Cornelis A Hoefnagel; Willem Nooijen
Radiation injury in the human kidney: a prospective analysis using specific scintigraphic and biochemical endpoints.
International journal of radiation oncology, biology, physics 1990;19(4):977-83.
1990: C Loesberg; H Van Rooij; Willem Nooijen; A J Meijer; Lou A Smets
Impaired mitochondrial respiration and stimulated glycolysis by m-iodobenzylguanidine (MIBG).
International journal of cancer. Journal international du cancer 1990;46(2):276-81.
1989: Johannes M G Bonfrer; Peter Bruning; Willem Nooijen
A simple method for the measurement of the steroid fraction bound to sex hormone binding globulin in serum.
Journal of steroid biochemistry 1989;33(2):227-31.
1989: Peter Bruning; Johannes M G Bonfrer; Augustinus A M Hart; E van der Linden; M de Jong-Bakker; A J Moolenaar; Willem Nooijen
Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer.
European journal of cancer & clinical oncology 1989;25(2):369-76.